Virtual Network's Login.
Chairs: Michael Hallek, Louis Staudt, Stephan Stilgenbauer, Andrei Thomas-Tikhonenko
SESSION I: MOLECULAR MECHANISMS OF B-CELL NEOPLASMS – FROM GENOME TO DIAGNOSTIC TOOLS AND PROGNOSTIC PREDICTION
Bcl-6 and related pathways in lymphomagenesis – Riccardo Dalla-Favera
B-cell receptor mediated signaling and the use of targeted therapies – Louis Staudt
Pre-B-Cell receptor signaling defines a distinct subtype of acute lymphoblastic leukaemia – Markus Müschen
Inducing non-cell autonomous killing of double-hit lymphoma – David M. Weinstock
Integration of genetic and clinical information into one score, the CLL-IPI project – Jasmin Bahlo
SESSION II: ROLE OF THE LYMPHOMA MICROENVIRONMENT
Targeting the microenvironment rather than the leukemic clone with kinase inhibitors – Michael Hallek
Functional interactions between malignant and non-malignant cells in lymphoma – Hans-Guido Wendel
Dissecting the complexity of CLL microenvironment – Federico Caligaris-Cappio
Drugs targeting the TME of Hodgkin lymphoma: the clinical story of Nivolumab and other PD1/PDL1 inhibitor – Peter Borchmann
SESSION III: EPIGENETICS REGULATION IN B-CELL CANCERS
Genomic profiling and clonal evolution under treatment of CLL lymphoma – Catherine Wu
Epigenetics – Christoph Plass
Epigenomic evolution in diffuse large B-cell lymphomas – Ari Melnick
SESSION IV: DISEASE ASSESSMENT IN LYMPHOMA
PET and CT imaging in Hodgkin lymphoma – Lena Specht
Imaging and circulating tumour DNA in lymphoma – Wyndham Wilson
How to use molecular profiling to manage CLL in 2016 – Eugen Tausch
Assessment of minimal residual disease in lymphoid malignancies – Michael Kneba
SESSION V: CELLULAR AND OTHER IMMUNOTHERAPIES FOR LYMPHOID MALIGNANCIES
History and future role of immune therapy in lymphoma – Ronald Levy
Allogeneic stem cell transplantation for lymphoid malignancies – coming to an end? – David Maloney
CART for lymphoid malignancies – Michael Hudecek
Mechanisms of resistance to CART-19: acquired mutations meet alternative splicing – Andrei Thomas-Tikhonenko
PD1/PDL1 inhibitors in lymphoid malignancies – Margaret Shipp
SESSION VI: UPDATE ON NOVEL AGENTS IN NHL
Mechanisms of BCL2 inhibitors – Anthony Letai
Development of targeted agents in ALL – Charles Mullighan
Clinical application of BCL 2 inhibition – John Seymour
BTK inhibition – Jeffrey Jones
New agents in the management of NHL – Gilles Salles
SESSION VII: STRATEGIES OF INTERNATIONAL STUDY GROUPS TO INTEGRATED GENOMICS, NOVEL AGENTS AND TRADITIONAL APPROACHES INTO ONE TREATMENT CONCEPT
The US trials on NHL – Richard Little
The UK trials on NHL – Ruth Pettengell
The GCLLSG trials – Michael Hallek
The Lysa trial landscape – Franck Morschhauser
The UK trials on CLL – Peter Hillmen
SESSION VIII: TREATMENT OF RARE ENTITIES: IMPORTANT BUT RARE
Treatment of paediatric lymphoma – Catherine Patte
Treatment of CNS lymphoma – Andres Ferreri
Treatment of Waldenström macroglobulinemia – Steven Treon
Treatment of hairy cell leukaemia – Brunangelo Falini
PANEL DISCUSSION: HOW TO ENSURE THAT BREAKTHROUGHS WILL HAPPEN NOW FOR NHL/CLL?
Biology – Louis Staudt
Recommendations for future research:
EHA research roadmap for lymphoma – Gilles Salles
ASH research roadmap for lymphoma – David M. Weinstock
Requirements for clinical breakthroughs in malignant lymphomas – Georg Lenz
Tools for the analysis of big data – Clemens Suter-Crazzolara
From the point of view of the patient:
The expectations of American patients – Brian Koffman
The expectations of European patients – Karen Van Rassel
